000167590 001__ 167590
000167590 005__ 20240229133544.0
000167590 0247_ $$2doi$$a10.1158/1055-9965.EPI-20-1599
000167590 0247_ $$2pmid$$apmid:33619022
000167590 0247_ $$2ISSN$$a1055-9965
000167590 0247_ $$2ISSN$$a1538-7755
000167590 0247_ $$2altmetric$$aaltmetric:100904833
000167590 037__ $$aDKFZ-2021-00450
000167590 041__ $$aeng
000167590 082__ $$a610
000167590 1001_ $$0P:(DE-He78)98a8f1a22ffc460364a8a34499118103$$aZheng, Guoqiao$$b0$$eFirst author$$udkfz
000167590 245__ $$aBeta-blockers use and risk of breast cancer in women with hypertension.
000167590 260__ $$aPhiladelphia, Pa.$$bAACR$$c2021
000167590 3367_ $$2DRIVER$$aarticle
000167590 3367_ $$2DataCite$$aOutput Types/Journal article
000167590 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1625048925_3341
000167590 3367_ $$2BibTeX$$aARTICLE
000167590 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000167590 3367_ $$00$$2EndNote$$aJournal Article
000167590 500__ $$a#EA:C020# / 30(5):965-973
000167590 520__ $$aThe risk of breast cancer among hypertensive patients who use beta-blockers has attracted attention. However, the evidence is inconsistent and investigation of the dose-specific associations for subtypes of beta-blockers are limited.By incorporating Swedish national registers, breast cancer risk was estimated in women with hypertension who used nonselective beta-blockers and beta-1 selective blockers compared with propensity score-matched non-users. The cumulative defined daily dose was used to study the dose-response association. Test of interaction between beta-blocker use and other antihypertensive medications was performed.Hypertensive patients taking beta-1 selective blockers (metoprolol, atenolol, bisoprolol) had an increased risk of breast cancer with a hazard ratio (HR) and 95% confidence interval (CI) of 2.39 (1.95-2.94), 2.31 (1.46-3.64), and 3.02 (2.09-4.36), respectively. All of the observed associations were dose-dependent (P trend <0.0001). No significant association was found for the nonselective beta-blocker (propranolol) except that among users of agents acting on the renin-angiotensin system, those who used propranolol had increased breast cancer risk. Modification of agents acting on the renin-angiotensin system on breast cancer risk was also observed for atenolol.The increased risk of breast cancer associates with the use of beta-1 selective blockers in a dose-response manner.Breast cancer surveillance is recommended for hypertensive female patients using beta-1 selective blockers.
000167590 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000167590 588__ $$aDataset connected to CrossRef, PubMed,
000167590 7001_ $$aSundquist, Jan$$b1
000167590 7001_ $$aSundquist, Kristina$$b2
000167590 7001_ $$aJi, Jianguang$$b3
000167590 773__ $$0PERI:(DE-600)2036781-8$$a10.1158/1055-9965.EPI-20-1599$$gp. cebp.1599.2020 -$$n5$$p965-973$$tCancer epidemiology, biomarkers & prevention$$v30$$x1538-7755$$y2021
000167590 909CO $$ooai:inrepo02.dkfz.de:167590$$pVDB
000167590 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)98a8f1a22ffc460364a8a34499118103$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000167590 9130_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000167590 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000167590 9141_ $$y2021
000167590 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER EPIDEM BIOMAR : 2018$$d2020-09-04
000167590 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-09-04
000167590 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-09-04
000167590 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-09-04
000167590 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2020-09-04
000167590 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-09-04
000167590 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-09-04
000167590 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2020-09-04
000167590 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-09-04
000167590 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-09-04
000167590 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-09-04
000167590 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCER EPIDEM BIOMAR : 2018$$d2020-09-04
000167590 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000167590 980__ $$ajournal
000167590 980__ $$aVDB
000167590 980__ $$aI:(DE-He78)C020-20160331
000167590 980__ $$aUNRESTRICTED